Traders Buy Johnson & Johnson (JNJ) on Weakness
Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Friday. $679.89 million flowed into the stock on the tick-up and $115.81 million flowed out of the stock on the tick-down, for a money net flow of $564.08 million into the stock. Of all companies tracked, Johnson & Johnson had the 6th highest net in-flow for the day. Johnson & Johnson traded down ($0.38) for the day and closed at $118.25
JNJ has been the topic of a number of recent analyst reports. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target on the stock in a report on Monday, August 22nd. Standpoint Research assumed coverage on Johnson & Johnson in a research note on Friday, May 20th. They issued a “sell” rating and a $94.00 target price on the stock. Leerink Swann restated an “outperform” rating and issued a $140.00 target price (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Friday, June 3rd. Finally, RBC Capital Markets restated an “outperform” rating and issued a $133.00 target price (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $119.10.
The firm’s 50 day moving average price is $120.86 and its 200-day moving average price is $115.84. The company has a market capitalization of $323.52 billion, a P/E ratio of 22.04 and a beta of 0.61.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/traders-buy-johnson-johnson-jnj-on-weakness.html
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. On average, equities research analysts expect that Johnson & Johnson will post $6.69 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 19th. Shareholders of record on Friday, August 5th were issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 0.98%. Johnson & Johnson’s dividend payout ratio is presently 60.15%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
A number of large investors have recently bought and sold shares of JNJ. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $2,532,680,000. Bank of Montreal Can purchased a new position in shares of Johnson & Johnson during the second quarter worth $858,505,000. Emerald Acquisition Ltd. purchased a new position in shares of Johnson & Johnson during the second quarter worth $805,455,000. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the last quarter. 65.31% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.